Clinical Trials List
2023-10-31 - 2027-12-31
Phase II
Recruiting4
ICD-10C76.0
Malignant neoplasm of head, face and neck
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9195.0
Malignant neoplasm of other and ill-defined sites of head, face and neck
-
-
Trial Applicant
GlaxoSmithKline
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/13
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 劉奕廷 無
- Chih-Chieh Yen 無
- Shang-Yin Wu 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
17 participants
-
Global
300 participants
